Sign in or create an account to add this stock to your watchlist.
About Visterra (NASDAQ:VIST)
Visterra Inc is a United States-based biotechnology company. The Company uses its Atomic Interaction Network analysis to identify disease targets and design effective therapeutics. The Company's technology is based on its Hierotope Platform, which identifies an area, or epitope, on the target protein, glycoprotein or glycan that is fundamental to its structure and function. The Company's Hierotope Platform is able to identify the region of the protein, or epitope, which is structurally constrained, and thus prevented from mutation over time or under immunological or therapeutic pressure. Its technology for creating potent and therapeutics is powered by the Company's computational tools and techniques, the core of which is called Atomic Interaction Network (AIN) analysis.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Visterra (NASDAQ:VIST) Frequently Asked Questions
What is Visterra's stock symbol?
Visterra trades on the NASDAQ under the ticker symbol "VIST."
When did Visterra IPO?
(VIST) raised $51 million in an initial public offering (IPO) on the week of January 30th 2017. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and Stifel served as the underwriters for the IPO and Needham & Company, Wedbus and PacGrow were co-managers.
Has Visterra been receiving favorable news coverage?
News coverage about VIST stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Visterra earned a news sentiment score of 0.04 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Visterra?
Shares of VIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Visterra?
Visterra's mailing address is 1 Kendall Sq Ste B3301, CAMBRIDGE, MA 02139-1604, United States. The biotechnology company can be reached via phone at +1-617-4981070.
MarketBeat Community Rating for Visterra (VIST)MarketBeat's community ratings are surveys of what our community members think about Visterra and other stocks. Vote "Outperform" if you believe VIST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIST will underperform the S&P 500 over the long term. You may vote once every thirty days.
Visterra (NASDAQ:VIST) Analyst Ratings History
(Data available from 5/22/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Visterra (NASDAQ:VIST) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Visterra (NASDAQ VIST) Insider Trading and Institutional Ownership History
Visterra (NASDAQ VIST) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Visterra (NASDAQ VIST) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Visterra (NASDAQ:VIST) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Visterra (NASDAQ:VIST) Income Statement, Balance Sheet and Cash Flow Statement
Visterra (NASDAQ VIST) Stock Chart for Tuesday, May, 22, 2018